S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:INCY

Incyte Stock Forecast, Price & News

$80.26
+2.76 (+3.56 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$76.56
Now: $80.26
$80.75
50-Day Range
$76.02
MA: $87.35
$100.50
52-Week Range
$62.48
Now: $80.26
$110.36
Volume1.80 million shs
Average Volume1.34 million shs
Market Capitalization$17.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Incyte logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700
Employees1,773
Year Founded1991

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$2.17 per share
Book Value$12.06 per share

Profitability

Net Income$446.91 million

Miscellaneous

Market Cap$17.64 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.85 out of 5 stars

Medical Sector

126th out of 1,968 stocks

Commercial Physical Research Industry

4th out of 42 stocks

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$80.26
+2.76 (+3.56 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Incyte (NASDAQ:INCY) Frequently Asked Questions

Is Incyte a buy right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Incyte stock.
View analyst ratings for Incyte
or view top-rated stocks.

What stocks does MarketBeat like better than Incyte?

Wall Street analysts have given Incyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Incyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Incyte
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) issued its earnings results on Monday, February, 8th. The biopharmaceutical company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.30. The biopharmaceutical company had revenue of $788.50 million for the quarter, compared to the consensus estimate of $654.08 million. Incyte had a negative trailing twelve-month return on equity of 13.66% and a negative net margin of 13.62%. Incyte's revenue for the quarter was up 36.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.65 EPS.
View Incyte's earnings history
.

How has Incyte's stock price been impacted by Coronavirus (COVID-19)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INCY stock has increased by 11.6% and is now trading at $80.26.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for INCY?

20 Wall Street analysts have issued 12-month price objectives for Incyte's stock. Their forecasts range from $70.00 to $124.00. On average, they expect Incyte's stock price to reach $102.93 in the next twelve months. This suggests a possible upside of 28.2% from the stock's current price.
View analysts' price targets for Incyte
or view top-rated stocks among Wall Street analysts.

Who are Incyte's key executives?

Incyte's management team includes the following people:
  • Mr. Herve Hoppenot, Chairman, Pres & CEO (Age 61, Pay $2.47M)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 50, Pay $1.2M)
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 58, Pay $847.81k)
  • Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA, Exec. VP & GM of North America (Age 63, Pay $803.14k)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 54, Pay $937.73k)
  • Mr. Michael James Morrissey, Exec. VP & Head of Global Technical Operations (Age 57)
  • Dr. Dashyant Dhanak Ph.D., Exec. VP & Chief Scientific Officer (Age 60)
  • Mr. Michael Booth DPhil, Divisional VP of Investor Relations & Corp. Social Responsibility (Age 50)
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel (Age 55)
  • Ms. Pamela M. Murphy, VP of Investor Relations & Corp. Communications (Age 70)

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte CEO Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among Incyte's employees.

Who are some of Incyte's key competitors?

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (14.83%), Baker BROS. Advisors LP (14.56%), BlackRock Inc. (8.13%), Renaissance Technologies LLC (2.69%), Dodge & Cox (1.49%) and UBS Asset Management Americas Inc. (1.11%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte
.

Which institutional investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including Caisse DE Depot ET Placement DU Quebec, Wells Fargo & Company MN, Renaissance Technologies LLC, Alliancebernstein L.P., First Trust Advisors LP, Frontier Capital Management Co. LLC, Northern Trust Corp, and Shikiar Asset Management Inc.. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte
or view top insider-selling stocks.

Which institutional investors are buying Incyte stock?

INCY stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Price T Rowe Associates Inc. MD, BlackRock Inc., Assenagon Asset Management S.A., Canada Pension Plan Investment Board, Candriam Luxembourg S.C.A., Nuveen Asset Management LLC, and Morgan Stanley. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Herve Hoppenot.
View insider buying and selling activity for Incyte
or or view top insider-buying stocks.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $80.26.

How much money does Incyte make?

Incyte has a market capitalization of $17.64 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis.

How many employees does Incyte have?

Incyte employs 1,773 workers across the globe.

When was Incyte founded?

Incyte was founded in 1991.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

Where are Incyte's headquarters?

Incyte is headquartered at 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.